BridgeBio Pharma (BBIO) Debt Ratio (2018 - 2026)

BridgeBio Pharma's Debt Ratio history runs 9 years deep, the most recent figure standing at 0.94 for Q1 2026.

• In Q1 2026, Debt Ratio changed N/A year-over-year to 0.94; the TTM figure through Mar 2026 stood at 0.94 (changed N/A YoY), while the FY2025 annual figure was 0.6, up 1.71% from the prior year.
• Debt Ratio came in at 0.94 for Q1 2026 at BridgeBio Pharma, up from 0.6 in the prior quarter.
• In the past five years, Debt Ratio ranged from a high of 0.94 in Q1 2026 to a low of 0.49 in Q2 2022.
• A 5-year average of 0.66 and a median of 0.66 in 2024 frame the typical range for Debt Ratio.
• Across the five-year window, Debt Ratio jumped 518.25% in 2022 and tumbled 37.32% in 2024, its largest moves.
• BridgeBio Pharma's Debt Ratio stood at 0.69 in 2022, then grew by 18.12% to 0.82 in 2023, then fell by 27.43% to 0.59 in 2024, then advanced by 1.71% to 0.6 in 2025, then surged by 55.87% to 0.94 in 2026.
• According to Business Quant data, Debt Ratio over the past three periods registered 0.94, 0.6, and 0.74 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison